In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
Fig 4
MTT assay showing the viability of prostate cell lines following treatment with the GnRH antagonist, degarelix.
(A) WPMY-1, (B) WPE1-NA22, (C) BPH-1, (D) PC-3, and (E) LNCaP. Data are expressed as the percentage of the respective controls and the average ± standard error. Each assay was done in triplicate in at least 3 independent experiments for each cell line. Two-way ANOVA indicated there was a significant difference overall for degarelix treatment (p<0.001), and the posttest indicated that there were differences against each control, as displayed in each graph (***p<0.001).